Striatal and Extra-Striatal Cholinergic Terminal Density in LRRK2-PD Mutation
Recruiting
Observational Study
Parkinson Disease
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 45 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 15 (estimated)
- Sponsor
- University of Michigan · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This study explores how a specific genetic mutation of leucine-rich repeat kinase 2 (LRRK2) affects individuals with Parkinson's disease (PD), comparing those with the mutation to others with Parkinson's disease and without the mutation (iPD). Participants will complete positron emission tomography (PET) and magnetic resonance imaging (MRI) brain imaging, cognitive tests, motor tests, sensory test…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Male or Female, age 45 years and over.
2. Diagnosis of PD based on the United Kingdom Parkinson's Disease Society Brain Bank Diagnostic Research Criteria (Hughes et al., 1992).
3. Presence of LRRK2 mutation as confirmed by referral from UM Movement Disorders clinic, medical r…
Contacts